{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:56:31Z","timestamp":1787169391034,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["EY034172"],"award-info":[{"award-number":["EY034172"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007414","name":"Horncrest Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007414","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Novel therapies for diabetes have potent effects on glycemic control, obesity, and cardiovascular risk reduction, but some, including the popular drug semaglutide, have also been implicated in worsening of diabetic retinopathy (DR). Given the ubiquity of these new agents, understanding the risks to vision is important. Here, we review the data for several newly available agents in terms of systemic efficacy and retinal safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Literature review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Novel antihyperglycemic treatments include incretin mimetics and enhancers, sodium-glucose cotransporter inhibitors, long-acting insulins, and insulin delivery systems. All improve glycemic control, and some have been shown to reduce major cardiovascular outcomes. In a pivotal trial, semaglutide was associated with approximately 75% increased risk of DR worsening. The novel long-acting insulin icodec, formulated for once weekly dosing, showed increased risk of DR worsening over a once daily insulin. No other recent antihyperglycemic agent was associated with DR worsening, although following the semaglutide trials, nearly all studies excluded patients with preexisting DR. Cases of DR worsening were rare in all instances. Dedicated safety studies for semaglutide in DR are currently underway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>For most patients being considered for treatment with a novel antihyperglycemic agent, benefits on systemic metabolic and cardiovascular health are very likely to outweigh potential retinal harms. Although the true risks of the new agents on DR are unclear because their safety data come from secondary end points, the most vulnerable patients are those with preexisting high-risk DR, poor baseline glycemic control, and using insulin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004252","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T18:01:17Z","timestamp":1723831277000},"page":"1851-1859","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3036-2665","authenticated-orcid":false,"given":"Rithwick","family":"Rajagopal","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, Saint Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250714","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R2-20250714","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250714","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20250714","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R5-20250714","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250714","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"R7-20250714","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"R8-20250714","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","article-title":"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"R9-20250714","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"R10-20250714","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"R11-20250714","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"R12-20250714","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20250714","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"R14-20250714","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20250714","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"R16-20250714","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.2337\/dc18-1355","article-title":"Retinopathy outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial","volume":"42","author":"Inzucchi","year":"2019","journal-title":"Diabetes Care"},{"key":"R17-20250714","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00125-009-1415-7","article-title":"Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study","volume":"52","author":"Rosenstock","year":"2009","journal-title":"Diabetologia"},{"key":"R18-20250714","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.2023.11313","article-title":"Once-weekly insulin icodec vs. once-daily insulin degludec in adults with insulin-Naive type 2 diabetes: the ONWARDS 3 Randomized Clinical Trial","volume":"330","author":"Lingvay","year":"2023","journal-title":"JAMA"},{"key":"R19-20250714","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/dc22-2395","article-title":"Novel once-weekly basal insulin Fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes","volume":"46","author":"Kazda","year":"2023","journal-title":"Diabetes Care"},{"key":"R20-20250714","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","article-title":"Multicenter, randomized trial of a bionic pancreas in type 1 diabetes","volume":"387","author":"Russell","year":"2022","journal-title":"N Engl J Med"},{"key":"R21-20250714","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2337\/dc19-2267","article-title":"Dual-hormone closed-loop system using a liquid stable glucagon formulation versus insulin-only closed-loop system compared with a predictive low glucose suspend system: an open-label, outpatient, single-center, crossover, randomized controlled trial","volume":"43","author":"Wilson","year":"2020","journal-title":"Diabetes Care"},{"key":"R22-20250714","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/dc19-1922","article-title":"A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial","volume":"43","author":"Haidar","year":"2020","journal-title":"Diabetes Care"},{"key":"R23-20250714","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"R24-20250714","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"R25-20250714","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsboll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R26-20250714","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"R27-20250714","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","article-title":"Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"47","author":"Lin","year":"2023","journal-title":"Diabetes Metab J"},{"key":"R28-20250714","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","article-title":"Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database","volume":"67","author":"Eleftheriadou","year":"2024","journal-title":"Diabetologia"},{"key":"R29-20250714","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R30-20250714","doi-asserted-by":"crossref","first-page":"dgz069","DOI":"10.1210\/clinem\/dgz069","article-title":"Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the AngioSafe type 2 diabetes study","volume":"105","author":"Gaborit","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20250714","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/diacare.24.4.631","article-title":"Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin","volume":"24","author":"Rosenstock","year":"2001","journal-title":"Diabetes Care"},{"key":"R33-20250714","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","article-title":"Standards for screeningand surveillance of ocular complications in people with diabetes SFDsg. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes","volume":"44","author":"Feldman-Billard","year":"2018","journal-title":"Diabetes Metab"},{"key":"R34-20250714","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R35-20250714","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diabetes Care"},{"key":"R36-20250714","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3928\/23258160-20200326-04","article-title":"Impact of systemic dipeptidyl peptidase-4 inhibitor use in diabetic macular edema","volume":"51","author":"Rahimy","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R37-20250714","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R38-20250714","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"R39-20250714","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"R40-20250714","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R41-20250714","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"R42-20250714","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"R43-20250714","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1210\/clinem\/dgab050","article-title":"SGLT2 inhibitor-induced low-grade ketonemia ameliorates retinal hypoxia in diabetic retinopathy-A novel hypothesis","volume":"106","author":"Mudaliar","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20250714","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/dom.15106","article-title":"Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: a population-based cohort study","volume":"25","author":"Larose","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R47-20250714","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMoa2303208","article-title":"Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin","volume":"389","author":"Rosenstock","year":"2023","journal-title":"N Engl J Med"},{"key":"R48-20250714","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2337\/dc22-2396","article-title":"Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-Naive patients with type 2 diabetes: a phase 2 randomized control trial","volume":"46","author":"Bue-Valleskey","year":"2023","journal-title":"Diabetes Care"},{"key":"R49-20250714","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.2337\/dc11-0102","article-title":"Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control","volume":"34","author":"Downie","year":"2011","journal-title":"Diabetes Care"},{"key":"R50-20250714","doi-asserted-by":"crossref","first-page":"e2126126","DOI":"10.1001\/jamanetworkopen.2021.26126","article-title":"Clinical and demographic factors associated with diabetic retinopathy among young patients with diabetes","volume":"4","author":"Ferm","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R51-20250714","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.oret.2020.06.016","article-title":"Diabetic retinopathy screening with automated retinal image analysis in a primary care setting improves adherence to ophthalmic care","volume":"5","author":"Liu","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R52-20250714","doi-asserted-by":"crossref","first-page":"4101890","DOI":"10.1155\/2016\/4101890","article-title":"Diabetic retinopathy screening ratio is improved when using a digital, nonmydriatic fundus camera onsite in a diabetes outpatient clinic","volume":"2016","author":"Roser","year":"2016","journal-title":"J Diabetes Res"},{"key":"R53-20250714","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaophthalmol.2014.4652","article-title":"Diabetes eye screening in urban settings serving minority populations: detection of diabetic retinopathy and other ocular findings using telemedicine","volume":"133","author":"Owsley","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R54-20250714","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/NRL.0b013e318272f7d7","article-title":"The use of retinal photography in nonophthalmic settings and its potential for neurology","volume":"18","author":"Perez","year":"2012","journal-title":"Neurologist"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T20:00:21Z","timestamp":1752523221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004252","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}